We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+1.09%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$101M
AUM Growth
-$14.5M
Cap. Flow
-$1.16M
Cap. Flow %
-1.15%
Top 10 Hldgs %
56.77%
Holding
80
New
12
Increased
15
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$11.9M
2
OVV icon
Ovintiv
OVV
+$2.03M
3
NVCR icon
NovoCure
NVCR
+$1.22M
4
PRTA icon
Prothena Corp
PRTA
+$886K
5
GPCR icon
Structure Therapeutics
GPCR
+$792K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$17.8M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.41M
3
UTHR icon
United Therapeutics
UTHR
+$971K
4
TVTX icon
Travere Therapeutics
TVTX
+$580K
5
MASI
Masimo
MASI
+$479K

Sector Composition

Rank Sector Weight
1 Healthcare 79.06%
2 Technology 14.1%
3 Energy 6.07%
4 Materials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMCI icon
26
Treace Medical Concepts
TMCI
$274M
$1.04M 1.03%
176,947
+12,000
+7% +$78.2K
SLDB icon
27
Solid Biosciences
SLDB
$843M
$871K 0.86%
178,768
+50,000
+39% +$177K
KNSA icon
28
Kiniksa Pharmaceuticals
KNSA
$4.83B
$830K 0.82%
30,000
-6
-0% -$153
FCX icon
29
Freeport-McMoran
FCX
$84.6B
$782K 0.78%
+18,033
New +$685K
KALV
30
DELISTED
KalVista Pharmaceuticals
KALV
$757K 0.75%
67,000
-2
-0% -$24
GPCR icon
31
Structure Therapeutics
GPCR
$3.34B
$747K 0.74%
+36,000
New +$792K
APGE icon
32
Apogee Therapeutics
APGE
$10.1B
$695K 0.69%
16,000
+8,000
+100% +$304K
OM icon
33
Outset Medical
OM
$76.4M
$664K 0.66%
34,584
+10,000
+41% +$156K
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.5B
$657K 0.65%
21,000
– –
RARE icon
35
Ultragenyx Pharmaceutical
RARE
$2.86B
$654K 0.65%
18,000
+2,000
+13% +$72.1K
AXSM icon
36
Axsome Therapeutics
AXSM
$11.6B
$626K 0.62%
6,000
– –
OLMA icon
37
Olema Pharmaceuticals
OLMA
$1.01B
$571K 0.57%
+134,000
New +$597K
SRRK icon
38
Scholar Rock
SRRK
$6.27B
$567K 0.56%
16,000
– –
NTLA icon
39
Intellia Therapeutics
NTLA
$1.56B
$563K 0.56%
+60,000
New +$493K
KIDS icon
40
OrthoPediatrics
KIDS
$501M
$558K 0.55%
26,000
+6,000
+30% +$130K
IMNM icon
41
Immunome
IMNM
$2.52B
$558K 0.55%
+60,000
New +$492K
XNCR icon
42
Xencor
XNCR
$1.4B
$550K 0.55%
70,000
+44,000
+169% +$395K
HALO icon
43
Halozyme
HALO
$9.21B
$520K 0.52%
10,000
– –
PACB icon
44
Pacific Biosciences
PACB
$419M
$496K 0.49%
+400,000
New +$462K
INBX icon
45
Inhibrx
INBX
$1.26B
$458K 0.46%
32,110
– –
MLTX icon
46
MoonLake Immunotherapeutics
MLTX
$1.61B
$378K 0.38%
8,000
– –
ATEC icon
47
Alphatec Holdings
ATEC
$1.29B
$366K 0.36%
33,000
– –
BCRX icon
48
BioCryst Pharmaceuticals
BCRX
$2.34B
$358K 0.36%
40,000
– –
BPMC
49
DELISTED
Blueprint Medicines
BPMC
$346K 0.34%
2,700
– –
CYTK icon
50
Cytokinetics
CYTK
$10.9B
$330K 0.33%
10,000
– –
1
2
3 4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Birchview Capital held 80 positions worth $101M, down 13% from $115M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Birchview Capital's Q2 2025 filing shows 12 new, 15 increased, 13 reduced and 9 closed positions. Its largest new stake was KLA: 158,480 shares worth $14.2M. The largest sale was Bristol-Myers Squibb, an estimated $17.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 96% a quarter earlier, followed by Technology and Energy.

  • Birchview Capital's largest Q2 2025 buy was KLA: 158,480 shares worth $14.2M.
  • Birchview Capital added most to Ovintiv in Q2 2025, an estimated $2.03M increase.
  • Birchview Capital's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $17.8M.
  • Birchview Capital fully exited SpringWorks Therapeutics in Q2 2025, selling an estimated $365K.
  • Birchview Capital's ten largest holdings make up 57% of its $101M portfolio in Q2 2025.
  • Birchview Capital opened 12 new positions and closed 9 in Q2 2025.
  • Birchview Capital's portfolio value fell 13% quarter-over-quarter to $101M.

Based on Birchview Capital's 13F filing for Q2 2025, filed 14 Aug 2025.